OFM
BCAX

Omega Fund Management’s Bicara Therapeutics BCAX Stock Holding History

Omega Fund Management’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$47.6M Buy
2,392,150
+187,500
+9% +$3.23M 29.16% 1
2025
Q4 		$37.1M Hold
2,204,650
– – 12.95% 4
2025
Q3 		$34.8M Hold
2,204,650
– – 15.66% 4
2025
Q2 		$20.5M Hold
2,204,650
– – 13.26% 5
2025
Q1 		$28.7M Hold
2,204,650
– – 16.95% 2
2024
Q4 		$38.4M Hold
2,204,650
– – 24.91% 1
2024
Q3 		$56.2M Buy
+2,204,650
New +$56.2M 35.09% 1

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RTM
Red Tree Management Redwood City, California $147M AUM 202.18% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RPSM
Royalty Pharma Sub-Manager New York $173M AUM

Omega Fund Management's BCAX Position: Q1 2026 in Review

Omega Fund Management increased its Bicara Therapeutics (BCAX) stake by 8.5% in Q1 2026, buying an estimated $3.23M and bringing the position to 2,392,150 shares worth $47.6M. The position accounts for 29.16% of the portfolio, ranked #1.

Omega Fund Management first reported a position in BCAX in Q3 2024 and has held it in 7 quarters since. The position peaked at $56.2M in Q3 2024. 146 funds tracked by Wall St. Rank hold BCAX as of Q1 2026.

  • Omega Fund Management held 2,392,150 shares of Bicara Therapeutics worth $47.6M as of Q1 2026.
  • Omega Fund Management bought 187,500 Bicara Therapeutics shares in Q1 2026, an estimated $3.23M.
  • Bicara Therapeutics made up 29.16% of Omega Fund Management's portfolio in Q1 2026, its #1 holding.
  • Omega Fund Management first reported a position in Bicara Therapeutics in Q3 2024 and has held it in 7 quarters since.
  • Omega Fund Management's Bicara Therapeutics position peaked at $56.2M in Q3 2024.
  • 146 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q1 2026.

Based on Omega Fund Management's 13F filing for Q1 2026, filed 15 May 2026.